Image source: Johnson & Johnson.
Biopharmaceutical pure play AbbVie (NYSE: ABBV) has been on a spending spree in an attempt to offset impending competition for a huge chunk of its revenue stream. Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is larger and more diverse, but its size alone makes continued growth a challenge.